Riskpilot← Back to searchSign inGet full accessALBMAR AB
ABActiveOrg 5590259239Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2024
SEK 1,1M
-80% vs 2023
EBITDA margin
-137.6%
-30593% vs 2023
Equity ratio
98.6%
Financial strength
Net profit 2024
SEK 144K
-40% vs 2023
| Revenue | SEK 1,1M | -80% |
| EBITDA | SEK -1,6M | -30593% |
| Net profit | SEK 144K | -40% |
| Total assets | SEK 6,8M | -28% |
| Equity | SEK 6,7M | -7% |
| Employees | 0 | — |
Legal name
ALBMAR AB
Org number
5590259239
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 september 2015
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten Styrelsen ska bestå av 1 styrelseledamot och 1 styrelsesuppleant.
Company purpose
Bolaget ska äga och förvalta fast egendom, aktier och värdepapper samt bedriva förenlig verksamhet inom arbetsförmedling, rekrytering.
Address
Email
molle@albmar.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 55 338 | 50 015 | 36 552 | 5 614 | 1 129 |
| Staff expenses | — | — | — | −1 427 | −1 424 |
| EBITDA | 8 211 | 3 174 | 4 765 | −5 | −1 554 |
| Depreciation & amort. | −0 | −0 | −13 | −35 | −51 |
| EBIT | 8 211 | 3 174 | 4 752 | −40 | −1 605 |
| Net financials | −1 | −1 318 | −948 | 295 | 481 |
| Profit before tax | 8 210 | 2 515 | 3 002 | 255 | 144 |
| Tax | −1 650 | −659 | −784 | −14 | — |
| Net profit | 6 560 | 1 856 | 2 218 | 241 | 144 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 32 343 | 22 367 | 11 388 | 9 418 | 6 751 |
| Equity | 6 610 | 7 417 | 7 634 | 7 195 | 6 659 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 25 733 | 14 950 | 2 486 | 955 | 92 |
| Total debt | 25 733 | 14 950 | 2 486 | 955 | 92 |
EBITDA margin
-137.6%
This company
15.8%
Market median
-971% vs market
20202024
Equity ratio
98.6%
This company
38.2%
Market median
+158% vs market
20202024
Return on equity
2.2%
This company
18.4%
Market median
-88% vs market
20202024
Net profit margin
12.8%
This company
8.1%
Market median
+58% vs market
20202024
Asset turnover
0.17×
This company
1.12×
Market median
-85% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MZ Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (2) | ||
AL Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 – 2025 |
AJ Audit | Audit | 2022 – 2026 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ALBMAR AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anas Latif Hsissen | Deputy Chief Executive Officer | 0 companies |
| Axel Johannes Nelén | Audit | 0 companies |
| Molle Zenelaj | Chief Executive Officer | 0 companies |